 |
|
Incidence and Prognostic Significance of Thrombocytopenia in Patients Treated With Prolonged Heparin Therapy
Gustavo B. F. Oliveira, MD;
Eric M. Crespo, MD;
Richard C. Becker, MD;
Emily F. Honeycutt, MBI;
Charles S. Abrams, MD;
Kevin J. Anstrom, PhD;
Peter B. Berger, MD;
Linda D. Davidson-Ray, MA;
Eric L. Eisenstein, DBA;
Neal S. Kleiman, MD;
David J. Moliterno, MD;
Stephan Moll, MD;
Lawrence Rice, MD;
Jo E. Rodgers, PharmD;
Steven R. Steinhubl, MD;
Victor F. Tapson, MD;
E. Magnus Ohman, MD;
Christopher B. Granger, MD; for the Complications After Thrombocytopenia Caused by Heparin (CATCH) Registry Investigators
Arch Intern Med. 2008;168(1):94-102.
Background Despite widespread heparin use in clinical practice, the associated development of thrombocytopenia is an underrecognized and undertreated complication.
Methods We analyzed data from consecutive hospitalized patients treated with heparin (unfractionated or low molecular weight) for 4 days or longer to determine the incidence, predictors, prognostic significance, and management of "thrombocytopenia," defined as a platelet count less than 150 x 109/L, reduction in platelet count of 50% or more from the admission level, or both.
Results We enrolled 2420 patients (median age, 65.2 years; 43.8% women) in 48 US hospitals. Thrombocytopenia occurred in 881 patients (36.4%; 95% confidence interval [CI], 34.5%-38.3%). Of those who developed thrombocytopenia, 5.1% died, compared with 1.6% of those without thrombocytopenia (odds ratio [OR], 3.4; 95% CI, 2.1-5.6; P < .001). Thrombocytopenia was also associated with greater risk of myocardial infarction (OR, 2.1; 95% CI, 1.5-2.8; P < .001) and congestive heart failure (OR, 1.3; 95% CI, 1.1-1.6; P = .01). After adjustment for important covariates, thrombocytopenia remained an independent predictor of thrombotic and hemorrhagic events. A relative reduction in platelet count of more than 70% was the strongest independent predictor of death (OR, 13.4; 95% CI, 6.5-27.6; P < .001), followed by a relative reduction in platelet count of 50% to 70%, worse Killip class, occurrence of thromboembolic complications, older age, and longer duration of heparin therapy.
Conclusions Thrombocytopenia occurs frequently after prolonged heparin therapy and is strongly associated with worse short-term clinical outcome. The relative reduction in platelet count is a powerful independent predictor of all-cause mortality in hospitalized patients.
Author Affiliations: Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina (Drs Oliveira, Becker, Anstrom, Berger, Eisenstein, Tapson, Ohman, and Granger and Mss Honeycutt and Davidson-Ray), and Department of Medicine and School of Pharmacy, University of North Carolina at Chapel Hill (Drs Crespo, Moll, Rodgers, and Ohman); Geisinger Health System, Danville, Pennsylvania (Dr Berger), and Department of Medicine, Pennsylvania School of Medicine, Philadelphia (Dr Abrams); Baylor College of Medicine, Houston, Texas (Drs Kleiman and Rice); and Department of Medicine, University of Kentucky, Lexington (Drs Moliterno and Steinhubl).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Thrombotic events in patients with antiplatelet factor 4/heparin antibodies
Mattioli et al.
Heart 2009;95:1350-1354.
ABSTRACT
| FULL TEXT
Heparin-Induced Thrombocytopenia: A Contemporary Clinical Approach to Diagnosis and Management
Shantsila et al.
Chest 2009;135:1651-1664.
ABSTRACT
| FULL TEXT
Adverse Prognostic Significance of Thrombocytopenia in Acute Coronary Syndrome: Can Anything Be Done About It?
Warkentin and Crowther
Circulation 2009;119:2420-2422.
FULL TEXT
Incidence and Prognostic Significance of Thrombocytopenia Developed During Acute Coronary Syndrome in Contemporary Clinical Practice
Wang et al.
Circulation 2009;119:2454-2462.
ABSTRACT
| FULL TEXT
Hypercoagulable States in Cardiovascular Disease
Chan et al.
Circulation 2008;118:2286-2297.
FULL TEXT
Incidence and Prognostic Significance of Thrombocytopenia in Patients Receiving Heparin Therapy
Kittisupamongkol
Arch Intern Med 2008;168:2170-2170.
FULL TEXT
Risk Factors for Thrombocytopenia in Patients Treated With Prolonged Heparin Therapy--Reply
Granger et al.
Arch Intern Med 2008;168:2171-2171.
FULL TEXT
Heparin and Thrombocytopenia: Guilty Till Proven Innocent?
Naina and Harris
Arch Intern Med 2008;168:2169-2170.
FULL TEXT
Risk Factors for Thrombocytopenia in Patients Treated With Prolonged Heparin Therapy
Williamson and Pilon
Arch Intern Med 2008;168:2170-2171.
FULL TEXT
|
